查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1823904

精神疾病治療市場報告：2031 年趨勢、預測與競爭分析

Psychotic Disorder Treatment Market Report: Trends, Forecast and Competitive Analysis to 2031
出版日期: | 出版商: Lucintel | 英文 150 Pages | 商品交期: 3個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

全球精神疾病治療市場前景光明，醫院藥局、零售藥局、藥局和電商市場都蘊藏著巨大的機會。預計2025年至2031年，全球精神疾病治療市場的複合年成長率將達6.1%。推動該市場發展的關鍵因素包括：精神疾病盛行率的上升、人們對精神疾病治療認知的不斷提高以及對有效藥物的需求不斷成長。

  • Lucintel 預測，在預測期內，非典型抗精神病藥物將成為所有藥物類型中成長最快的。
  • 從分銷管道來看，醫院藥房預計將實現最高成長。
  • 按地區分類，預計亞太地區將在預測期內實現最高成長。

心理健康治療市場的新趨勢

心理健康治療市場正在經歷一場動態變革，其特點包括藥物研發的重大進展、對個人化治療的日益重視以及數位科技的融合。這些新興趨勢正在重新定義治療模式，並促進更全面、更便利的心理健康障礙治療方法的出現。

  • 新型藥物療法和作用機制：此趨勢涉及開發針對傳統多巴胺拮抗作用以外的新型生物路徑的抗精神病藥物。例如，作用於毒蕈鹼乙醯膽鹼受體的藥物（M1/M4促效劑）顯示出良好的前景，可能對陽性、陰性和認知症狀有更好的療效，且副作用更少。
  • 長效注射抗精神病藥物：長效抗精神病藥物製劑的日益發展和應用是一個重要趨勢。長效注射抗精神病藥物可透過減少給藥頻率來提高藥物依從性，而給藥頻率是慢性精神疾病管理的一大挑戰，進而改善治療效果並降低復發率。
  • 數位治療與遠距精神病學：數位健康解決方案（例如用於症狀追蹤的行動應用程式、虛擬實境 (VR) 治療和遠距精神病學）的整合是一個新興趨勢。這些技術可以增強患者參與度，提供遠距支持，改善醫療服務可近性，並提供個人化介入措施，尤其適用於醫療資源匱乏地區的患者。
  • 個人化醫療：此趨勢著重於根據患者的個別特徵（例如基因圖譜和生物標記）制定個人化治療方案。透過識別患者疾病的特定通路，個人化醫療旨在最佳化藥物選擇和劑量，並減少副作用，從而提供更有效、更個人化的治療。
  • 整合心理社會介入：人們越來越重視將藥物治療與綜合心理社會介入措施（例如認知行為療法 (CBT)、家庭心理教育和就業支持）相結合。這種趨勢提倡一種整體療法，不僅要解決症狀，還要促進功能恢復並改善患者的生活品質。

這些新興趨勢透過提供更有針對性和更有效的藥物干預、透過創新的藥物輸送來提高患者依從性、透過數位健康提高可及性和參與度以及促進整體和個人化的治療方法，正在顯著重塑心理健康治療市場。

精神疾病治療市場的最新趨勢

心理健康治療市場近期取得了多項關鍵進展，反映出業界正大力推動提高療效、增強患者依從性以及更全面的心理健康護理方法。這些進步對於滿足精神疾病患者的複雜需求至關重要。

  • FDA核准新型作用機轉抗精神病藥物：FDA核准新型作用機轉抗精神病藥物是一項重要進展。例如，曲司溴銨（Xanomeline Trospium）針對膽鹼能受體，而非僅靶向多巴胺受體。這代表著模式轉移，可能帶來更佳療效和更獨特的副作用。
  • 長效注射劑的進展：近年來，長效注射抗精神病藥物的創新和新核准不斷湧現。這些劑型，例如Paliperidone palmitate），旨在透過延長給藥間隔來提高依從性，降低復發率，並使治療更加便捷。
  • 精神疾病數位療法和虛擬實境 (VR) 的發展：數位療法和虛擬實境 (VR) 解決方案正在不斷開發和應用，以補充傳統療法。例如，OxfordVR 的 VR 顛覆性技術可在身臨其境型虛擬場景中提供自動化認知行為療法 (CBT)，並在減少偏執和改善生活品質方面顯示出顯著的益處。
  • 關注負面症狀和認知症狀：近期的研究和發展工作越來越側重於精神疾病的負面症狀和認知症狀。各公司正在探索新的化合物和方法，以改善這些嚴重影響日常生活的衰弱症狀。
  • 策略聯盟與不斷成長的產品線：製藥公司正在尋求策略聯盟與合作，以加速藥物開發。例如，勃林格殷格翰與Sosei集團就治療思覺失調症的GPR52促效劑展開合作，這顯示該公司擁有強大的、針對多種疾病的新型療法產品線。

這些最新趨勢共同影響著心理健康治療市場，包括引入具有不同作用機制的新型治療方案、透過先進的配方提高藥物依從性、透過使用數位健康改善獲取和結果、以及關注服務不足的症狀區域，最終促進整體患者照護。

目錄

第1章執行摘要

第2章 市場概況

  • 背景和分類
  • 供應鏈

第3章：市場趨勢及預測分析

  • 產業驅動力與挑戰
  • PESTLE分析
  • 專利分析
  • 法規環境

4. 全球精神病治療市場（依藥物類型）

  • 概述
  • 吸引力分析：按藥物類型
  • 非典型抗精神病藥物：趨勢與預測（2019-2031）
  • 吩噻嗪類抗精神病藥物：趨勢與預測（2019-2031）
  • 噻噸類：趨勢與預測（2019-2031）
  • 其他抗精神病藥物：趨勢與預測（2019-2031）

5. 全球精神病治療市場（按適應症）

  • 概述
  • 吸引力分析：按適應症
  • 思覺失調症：趨勢與預測（2019-2031）
  • 雙極性情感障礙：趨勢與預測（2019-2031）
  • 妄想症：趨勢與預測（2019-2031）
  • 藥物誘發精神病：趨勢與預測（2019-2031）
  • 器質性精神病：趨勢與預測（2019-2031）

6. 全球精神疾病治療市場（依通路）

  • 概述
  • 吸引力分析：按分銷管道
  • 醫院藥局：趨勢與預測（2019-2031）
  • 零售藥局：趨勢與預測（2019-2031）
  • 藥局：趨勢與預測（2019-2031）
  • 電子商務：趨勢與預測（2019-2031）
  • 其他：趨勢與預測（2019-2031）

第7章區域分析

  • 概述
  • 全球精神科治療市場（按地區）

第8章：北美心理健康治療市場

  • 概述
  • 北美精神病治療市場（按藥物類型）
  • 北美精神病治療市場（按分銷管道）
  • 美國心理健康治療市場
  • 墨西哥的精神健康治療市場
  • 加拿大心理健康治療市場

9.歐洲心理健康治療市場

  • 概述
  • 歐洲精神病治療市場（按藥物類型）
  • 歐洲精神病治療市場（按分銷管道）
  • 德國心理健康治療市場
  • 法國心理健康治療市場
  • 西班牙的精神健康治療市場
  • 義大利心理健康治療市場
  • 英國心理健康治療市場

第10章：亞太心理健康治療市場

  • 概述
  • 亞太地區精神病治療市場（依藥物類型）
  • 亞太地區精神疾病治療市場（依通路）
  • 日本心理健康治療市場
  • 印度精神疾病治療市場
  • 中國心理健康治療市場
  • 韓國心理健康治療市場
  • 印尼的精神疾病治療市場

第 11 章世界其他地區（ROW）精神障礙治療市場

  • 概述
  • 其他地區精神病治療市場（按藥物類型）
  • 其他地區精神疾病治療市場（依通路）
  • 中東心理健康治療市場
  • 南美洲心理健康治療市場
  • 非洲心理健康治療市場

第12章 競爭分析

  • 產品系列分析
  • 營運整合
  • 波特五力分析
    • 競爭對手之間的競爭
    • 買方的議價能力
    • 供應商的議價能力
    • 替代品的威脅
    • 新進入者的威脅
  • 市佔率分析

第13章：機會與策略分析

  • 價值鏈分析
  • 成長機會分析
    • 按藥物類型分類的成長機會
    • 按適應症分類的成長機會
    • 分銷通路的成長機會
  • 全球心理健康治療市場的新趨勢
  • 戰略分析
    • 新產品開發
    • 認證和許可
    • 合併、收購、協議、合作和合資企業

第14章 價值鏈主要企業的公司簡介

  • Competitive Analysis
  • H. Lundbeck
  • Otsuka Pharmaceutical
  • Janssen Pharmaceuticals
  • Eli Lilly and Company
  • Allergan
  • Teva Pharmaceutical Industries
  • Dr. Reddy's Laboratories
  • Sumitomo Dainippon Pharma
  • Alkermes
  • Bristol-Myers Squibb Company

第15章 附錄

  • 圖表目錄
  • 表格列表
  • 調查方法
  • 免責聲明
  • 版權
  • 簡稱和技術單位

The future of the global psychotic disorder treatment market looks promising with opportunities in the hospital pharmacy, retail pharmacy, drug store and e-commerce markets. The global psychotic disorder treatment market is expected to grow with a CAGR of 6.1% from 2025 to 2031. The major drivers for this market are the increasing prevalence of mental health disorders, the rising awareness about psychiatric treatments, and the growing demand for effective medications.

  • Lucintel forecasts that, within the drug type category, atypical antipsychotic is expected to witness the highest growth over the forecast period.
  • Within the distribution channel category, hospital pharmacy is expected to witness the highest growth.
  • In terms of region, APAC is expected to witness the highest growth over the forecast period.

Emerging Trends in the Psychotic Disorder Treatment Market

The psychotic disorder treatment market is experiencing dynamic shifts, characterized by significant advancements in drug development, a growing emphasis on personalized care, and the integration of digital technologies. These emerging trends are redefining treatment paradigms and fostering a more holistic and accessible approach to managing mental health conditions.

  • Novel Drug Therapies and Mechanisms of Action: This trend involves the development of antipsychotic medications targeting new biological pathways beyond traditional dopamine antagonism. For instance, drugs acting on muscarinic acetylcholine receptors (M1/M4 agonists) are showing promise, offering potentially better efficacy for positive, negative, and cognitive symptoms with fewer side effects.
  • Long-Acting Injectable Antipsychotics: The increasing development and adoption of LAI formulations for antipsychotic drugs is a significant trend. LAIs improve medication adherence by reducing the frequency of dosing, which is a major challenge in managing chronic psychotic disorders, leading to better treatment outcomes and reduced relapse rates.
  • Digital Therapeutics and Telepsychiatry: The integration of digital health solutions, including mobile apps for symptom tracking, virtual reality (VR) therapy, and telepsychiatry, is an emerging trend. These technologies enhance patient engagement, provide remote support, improve access to care, and offer personalized interventions, particularly for individuals in underserved areas.
  • Personalized Medicine Approaches: This trend focuses on tailoring treatment plans based on individual patient characteristics, including genetic profiles and biomarkers. By identifying specific pathways involved in a patient's illness, personalized medicine aims to optimize drug selection, dosage, and reduce adverse effects, leading to more effective and individualized care.
  • Integration of Psychosocial Interventions: There's a growing emphasis on integrating pharmacotherapy with comprehensive psychosocial interventions, such as cognitive-behavioral therapy (CBT), family psychoeducation, and supported employment. This trend promotes a holistic approach, addressing not only symptoms but also functional recovery and improving quality of life for patients.

These emerging trends are profoundly reshaping the psychotic disorder treatment market by offering more targeted and effective pharmacological interventions, improving patient adherence through innovative drug delivery, enhancing accessibility and engagement via digital health, and promoting a holistic, personalized approach to care.

Recent Developments in the Psychotic Disorder Treatment Market

The psychotic disorder treatment market has witnessed several pivotal recent developments, reflecting a strong industry drive towards improved efficacy, enhanced patient compliance, and a more comprehensive approach to mental health care. These advancements are crucial for addressing the complex needs of individuals with psychotic disorders.

  • FDA Approval of Novel Mechanism Antipsychotics: A significant development is the FDA approval of antipsychotic drugs with new mechanisms of action, such as xanomeline-trospium, which targets cholinergic receptors instead of solely dopamine receptors. This represents a paradigm shift, offering potentially better efficacy and a different side effect profile.
  • Advancements in Long-Acting Injectable Formulations: Recent years have seen continued innovation and new approvals for long-acting injectable antipsychotics. These formulations, such as new versions of paliperidone palmitate (e.g., Invega Hafyera), aim to improve adherence and reduce relapse rates by offering extended dosing intervals, making treatment more convenient.
  • Growth in Digital Therapeutics and VR for Psychosis: There's an increasing development and application of digital therapeutics and virtual reality (VR) solutions to complement traditional treatments. For instance, OxfordVR's gamechanger VR offers automated CBT in immersive virtual scenarios, demonstrating significant benefits in reducing paranoia and improving quality of life.
  • Focus on Negative and Cognitive Symptoms: Recent R&D efforts are increasingly targeting the negative and cognitive symptoms of psychotic disorders, which are often poorly addressed by existing medications. Companies are exploring novel compounds and approaches to improve these debilitating symptoms, which significantly impact daily functioning.
  • Strategic Collaborations and Pipeline Growth: Pharmaceutical companies are engaging in more strategic partnerships and collaborations to accelerate drug development. Boehringer Ingelheim and Sosei Group Corporation's collaboration on GPR52 agonists for schizophrenia is an example, indicating a robust pipeline of new therapies addressing various symptoms.

These recent developments are collectively impacting the psychotic disorder treatment market by introducing novel treatment options with different mechanisms, enhancing medication adherence through advanced formulations, leveraging digital health for improved access and outcomes, and focusing on underserved symptom domains, ultimately advancing holistic patient care.

Strategic Growth Opportunities in the Psychotic Disorder Treatment Market

The psychotic disorder treatment market presents numerous strategic growth opportunities across key applications, driven by increasing disease prevalence, a focus on improving patient outcomes, and advancements in therapeutic approaches. Capitalizing on these opportunities requires targeted innovation and a patient-centric approach.

  • Schizophrenia Treatment Innovations: Schizophrenia remains a primary application with significant growth potential. Opportunities exist in developing new antipsychotics with improved efficacy for negative and cognitive symptoms, long-acting injectables for better adherence, and personalized medicine approaches based on genetic markers to optimize treatment.
  • Bipolar Disorder Management: The segment for bipolar disorder treatment offers substantial growth, particularly in developing novel mood stabilizers and atypical antipsychotics that provide comprehensive symptom control with fewer side effects. There's a need for therapies that effectively manage both manic and depressive episodes.
  • Early Intervention and First-Episode Psychosis: Focusing on early intervention programs and treatments for first-episode psychosis is a crucial growth area. Early and effective treatment can significantly alter disease trajectory, improve long-term outcomes, and reduce the burden of illness, creating a demand for rapid diagnostic and therapeutic interventions.
  • Treatment-Resistant Psychosis: A significant unmet need exists for effective treatments for patients with treatment-resistant psychosis. Strategic opportunities involve developing novel compounds or combination therapies that can address this challenging patient population, potentially through different pharmacological pathways or augmentation strategies.
  • Digital Health Integration: Leveraging digital therapeutics, telemedicine, and remote monitoring platforms offers immense growth potential. These applications can improve medication adherence, provide continuous symptom tracking, facilitate psychotherapy delivery, and enhance access to care, especially for patients in underserved areas or those preferring discreet support.

These strategic growth opportunities are profoundly impacting the psychotic disorder treatment market by directing R&D towards unmet needs, fostering innovation in drug delivery, and integrating digital solutions to enhance patient engagement and access. This diversification and patient-centric approach are crucial for advancing mental health care globally.

Psychotic Disorder Treatment Market Driver and Challenges

The psychotic disorder treatment market is influenced by a dynamic interplay of various technological, economic, and regulatory factors. Its growth trajectory is significantly propelled by drivers that boost demand and innovation, while simultaneously facing notable challenges that necessitate strategic adaptations for sustained expansion and broader market penetration.

The factors responsible for driving the psychotic disorder treatment market include:

1. Increasing Prevalence of Psychotic Disorders: The rising global incidence and diagnosis of psychotic disorders like schizophrenia and bipolar disorder are primary market drivers. Factors such as changing lifestyles, increased stress, and improved diagnostic capabilities contribute to an expanding patient pool requiring treatment.

2. Advancements in Antipsychotic Drug Development: Continuous R&D leading to newer generations of antipsychotics (atypical, third-generation) with improved efficacy, better side effect profiles, and novel mechanisms of action is a significant driver. This includes the development of long-acting injectables (LAIs) enhancing adherence.

3. Growing Awareness and Destigmatization of Mental Health: Increased public awareness campaigns, government initiatives, and reduced stigma surrounding mental illness encourage more individuals to seek diagnosis and treatment. This improved access to care directly translates into higher demand for therapeutic interventions.

4. Favorable Reimbursement Policies and Healthcare Spending: Enhanced healthcare coverage and increased government and private sector spending on mental health services in many countries are driving market growth. This improves patient access to medications and therapeutic support, especially in developed economies.

5. Integration of Digital Health and Telepsychiatry: The rapid adoption of digital therapeutics and telepsychiatry platforms, especially accelerated by recent global health events, significantly drives market access. These technologies facilitate remote consultations, medication management, and psychological support, overcoming geographical barriers.

Challenges in the psychotic disorder treatment market are:

1. High Cost of Novel Therapies: The development and commercialization of new, innovative antipsychotic drugs, particularly those with complex mechanisms or advanced formulations like LAIs, entail high R&D costs, leading to high prices that can limit patient access and reimbursement in some healthcare systems.

2. Medication Non-Adherence and Relapse Rates: Despite advancements, non-adherence to medication remains a significant challenge in managing chronic psychotic disorders, leading to frequent relapses and poorer patient outcomes. This necessitates continuous efforts in developing more convenient formulations and supportive interventions.

3. Persistent Stigma and Misconceptions: Despite growing awareness, societal stigma and misconceptions surrounding psychotic disorders can still deter individuals from seeking early diagnosis and consistent treatment. This impacts treatment initiation, adherence, and overall patient integration into society.

The psychotic disorder treatment market is dynamically driven by the increasing prevalence of mental illnesses, continuous innovation in drug development, and growing mental health awareness. However, significant challenges such as the high cost of advanced therapies, persistent issues with medication non-adherence, and enduring societal stigma demand concerted efforts from pharmaceutical companies, healthcare providers, and policymakers to ensure equitable access and optimal patient outcomes.

List of Psychotic Disorder Treatment Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies psychotic disorder treatment companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the psychotic disorder treatment companies profiled in this report include-

  • H. Lundbeck
  • Otsuka Pharmaceutical
  • Janssen Pharmaceuticals
  • Eli Lilly and Company
  • Allergan
  • Teva Pharmaceutical Industries
  • Dr. Reddy's Laboratories
  • Sumitomo Dainippon Pharma
  • Alkermes
  • Bristol-Myers Squibb Company

Psychotic Disorder Treatment Market by Segment

The study includes a forecast for the global psychotic disorder treatment market by drug type, indication, distribution channel, and region.

Psychotic Disorder Treatment Market by Drug Type [Value from 2019 to 2031]:

  • Atypical Antipsychotics
  • Phenothiazine Antipsychotics
  • Thioxanthenes
  • Miscellaneous Antipsychotics Agents

Psychotic Disorder Treatment Market by Indication [Value from 2019 to 2031]:

  • Schizophrenia
  • Bipolar Disorder
  • Delusional Disorder
  • Drug Induced Psychosis
  • Organic Psychosis

Psychotic Disorder Treatment Market by Region [Value from 2019 to 2031]:

  • North America
  • Europe
  • Asia Pacific
  • The Rest of the World

Country Wise Outlook for the Psychotic Disorder Treatment Market

The psychotic disorder treatment market is witnessing a profound transformation, driven by an escalating global prevalence of mental health conditions, increasing awareness, and significant advancements in pharmacotherapy and digital health solutions. This evolution is marked by a shift towards more targeted, patient-centric, and accessible treatment options, aiming to improve adherence and long-term outcomes for individuals living with conditions like schizophrenia and bipolar disorder.

  • United States: The U.S. market is a leader in adopting novel treatments, including long-acting injectables (LAIs) and new mechanisms of action. High healthcare spending and robust R&D by pharmaceutical companies are driving innovations, with a focus on addressing treatment-resistant cases and improving patient adherence through advanced formulations.
  • China: China market is rapidly expanding, fueled by a growing patient pool and increasing government investment in mental healthcare infrastructure. Local pharmaceutical companies are developing generic versions of antipsychotics, while also exploring digital health solutions to improve access and reduce the stigma associated with mental health treatment.
  • Germany: Germany market benefits from a well-established healthcare system and a strong emphasis on comprehensive mental health care. There's a growing adoption of advanced antipsychotics, coupled with integrated care models that combine pharmacotherapy with psychosocial interventions to improve patient outcomes and quality of life.
  • India: India market for psychotic disorder treatment is nascent but growing, driven by increasing awareness and government initiatives to destigmatize mental illness. Demand for affordable generic antipsychotics is high, while increasing investments in R&D are slowly bringing newer, more effective treatments to a larger patient population.
  • Japan: Japan market is characterized by a high focus on precision medicine and patient compliance. Japanese pharmaceutical companies are at the forefront of developing novel compounds and advanced formulations, particularly long-acting injectables, aimed at improving treatment adherence and reducing side effects for long-term management.

Features of the Global Psychotic Disorder Treatment Market

  • Market Size Estimates: Psychotic disorder treatment market size estimation in terms of value ($B).
  • Trend and Forecast Analysis: Market trends (2019 to 2024) and forecast (2025 to 2031) by various segments and regions.
  • Segmentation Analysis: Psychotic disorder treatment market size by drug type, indication, distribution channel, and region in terms of value ($B).
  • Regional Analysis: Psychotic disorder treatment market breakdown by North America, Europe, Asia Pacific, and Rest of the World.
  • Growth Opportunities: Analysis of growth opportunities in different drug type, indication, distribution channel, and regions for the psychotic disorder treatment market.
  • Strategic Analysis: This includes M&A, new product development, and competitive landscape of the psychotic disorder treatment market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

This report answers following 11 key questions:

  • Q.1. What are some of the most promising, high-growth opportunities for the psychotic disorder treatment market by drug type (atypical antipsychotics, phenothiazine antipsychotics, thioxanthenes, and miscellaneous antipsychotics agents), indication (schizophrenia, bipolar disorder, delusional disorder, drug induced psychosis, and organic psychosis), distribution channel (hospital pharmacies, retail pharmacies, drug store, e-commerce, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
  • Q.2. Which segments will grow at a faster pace and why?
  • Q.3. Which region will grow at a faster pace and why?
  • Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
  • Q.5. What are the business risks and competitive threats in this market?
  • Q.6. What are the emerging trends in this market and the reasons behind them?
  • Q.7. What are some of the changing demands of customers in the market?
  • Q.8. What are the new developments in the market? Which companies are leading these developments?
  • Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
  • Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
  • Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Market Overview

  • 2.1 Background and Classifications
  • 2.2 Supply Chain

3. Market Trends & Forecast Analysis

  • 3.2 Industry Drivers and Challenges
  • 3.3 PESTLE Analysis
  • 3.4 Patent Analysis
  • 3.5 Regulatory Environment

4. Global Psychotic Disorder Treatment Market by Drug Type

  • 4.1 Overview
  • 4.2 Attractiveness Analysis by Drug Type
  • 4.3 Atypical Antipsychotics: Trends and Forecast (2019-2031)
  • 4.4 Phenothiazine Antipsychotics: Trends and Forecast (2019-2031)
  • 4.5 Thioxanthenes: Trends and Forecast (2019-2031)
  • 4.6 Miscellaneous Antipsychotics Agents: Trends and Forecast (2019-2031)

5. Global Psychotic Disorder Treatment Market by Indication

  • 5.1 Overview
  • 5.2 Attractiveness Analysis by Indication
  • 5.3 Schizophrenia: Trends and Forecast (2019-2031)
  • 5.4 Bipolar Disorder: Trends and Forecast (2019-2031)
  • 5.5 Delusional Disorder: Trends and Forecast (2019-2031)
  • 5.6 Drug Induced Psychosis: Trends and Forecast (2019-2031)
  • 5.7 Organic Psychosis: Trends and Forecast (2019-2031)

6. Global Psychotic Disorder Treatment Market by Distribution Channel

  • 6.1 Overview
  • 6.2 Attractiveness Analysis by Distribution Channel
  • 6.3 Hospital Pharmacies: Trends and Forecast (2019-2031)
  • 6.4 Retail Pharmacies: Trends and Forecast (2019-2031)
  • 6.5 Drug Store: Trends and Forecast (2019-2031)
  • 6.6 e-Commerce: Trends and Forecast (2019-2031)
  • 6.7 Others: Trends and Forecast (2019-2031)

7. Regional Analysis

  • 7.1 Overview
  • 7.2 Global Psychotic Disorder Treatment Market by Region

8. North American Psychotic Disorder Treatment Market

  • 8.1 Overview
  • 8.2 North American Psychotic Disorder Treatment Market by Drug Type
  • 8.3 North American Psychotic Disorder Treatment Market by Distribution Channel
  • 8.4 United States Psychotic Disorder Treatment Market
  • 8.5 Mexican Psychotic Disorder Treatment Market
  • 8.6 Canadian Psychotic Disorder Treatment Market

9. European Psychotic Disorder Treatment Market

  • 9.1 Overview
  • 9.2 European Psychotic Disorder Treatment Market by Drug Type
  • 9.3 European Psychotic Disorder Treatment Market by Distribution Channel
  • 9.4 German Psychotic Disorder Treatment Market
  • 9.5 French Psychotic Disorder Treatment Market
  • 9.6 Spanish Psychotic Disorder Treatment Market
  • 9.7 Italian Psychotic Disorder Treatment Market
  • 9.8 United Kingdom Psychotic Disorder Treatment Market

10. APAC Psychotic Disorder Treatment Market

  • 10.1 Overview
  • 10.2 APAC Psychotic Disorder Treatment Market by Drug Type
  • 10.3 APAC Psychotic Disorder Treatment Market by Distribution Channel
  • 10.4 Japanese Psychotic Disorder Treatment Market
  • 10.5 Indian Psychotic Disorder Treatment Market
  • 10.6 Chinese Psychotic Disorder Treatment Market
  • 10.7 South Korean Psychotic Disorder Treatment Market
  • 10.8 Indonesian Psychotic Disorder Treatment Market

11. ROW Psychotic Disorder Treatment Market

  • 11.1 Overview
  • 11.2 ROW Psychotic Disorder Treatment Market by Drug Type
  • 11.3 ROW Psychotic Disorder Treatment Market by Distribution Channel
  • 11.4 Middle Eastern Psychotic Disorder Treatment Market
  • 11.5 South American Psychotic Disorder Treatment Market
  • 11.6 African Psychotic Disorder Treatment Market

12. Competitor Analysis

  • 12.1 Product Portfolio Analysis
  • 12.2 Operational Integration
  • 12.3 Porter's Five Forces Analysis
    • Competitive Rivalry
    • Bargaining Power of Buyers
    • Bargaining Power of Suppliers
    • Threat of Substitutes
    • Threat of New Entrants
  • 12.4 Market Share Analysis

13. Opportunities & Strategic Analysis

  • 13.1 Value Chain Analysis
  • 13.2 Growth Opportunity Analysis
    • 13.2.1 Growth Opportunities by Drug Type
    • 13.2.2 Growth Opportunities by Indication
    • 13.2.3 Growth Opportunities by Distribution Channel
  • 13.3 Emerging Trends in the Global Psychotic Disorder Treatment Market
  • 13.4 Strategic Analysis
    • 13.4.1 New Product Development
    • 13.4.2 Certification and Licensing
    • 13.4.3 Mergers, Acquisitions, Agreements, Collaborations, and Joint Ventures

14. Company Profiles of the Leading Players Across the Value Chain

  • 14.1 Competitive Analysis
  • 14.2 H. Lundbeck
    • Company Overview
    • Psychotic Disorder Treatment Business Overview
    • New Product Development
    • Merger, Acquisition, and Collaboration
    • Certification and Licensing
  • 14.3 Otsuka Pharmaceutical
    • Company Overview
    • Psychotic Disorder Treatment Business Overview
    • New Product Development
    • Merger, Acquisition, and Collaboration
    • Certification and Licensing
  • 14.4 Janssen Pharmaceuticals
    • Company Overview
    • Psychotic Disorder Treatment Business Overview
    • New Product Development
    • Merger, Acquisition, and Collaboration
    • Certification and Licensing
  • 14.5 Eli Lilly and Company
    • Company Overview
    • Psychotic Disorder Treatment Business Overview
    • New Product Development
    • Merger, Acquisition, and Collaboration
    • Certification and Licensing
  • 14.6 Allergan
    • Company Overview
    • Psychotic Disorder Treatment Business Overview
    • New Product Development
    • Merger, Acquisition, and Collaboration
    • Certification and Licensing
  • 14.7 Teva Pharmaceutical Industries
    • Company Overview
    • Psychotic Disorder Treatment Business Overview
    • New Product Development
    • Merger, Acquisition, and Collaboration
    • Certification and Licensing
  • 14.8 Dr. Reddy's Laboratories
    • Company Overview
    • Psychotic Disorder Treatment Business Overview
    • New Product Development
    • Merger, Acquisition, and Collaboration
    • Certification and Licensing
  • 14.9 Sumitomo Dainippon Pharma
    • Company Overview
    • Psychotic Disorder Treatment Business Overview
    • New Product Development
    • Merger, Acquisition, and Collaboration
    • Certification and Licensing
  • 14.10 Alkermes
    • Company Overview
    • Psychotic Disorder Treatment Business Overview
    • New Product Development
    • Merger, Acquisition, and Collaboration
    • Certification and Licensing
  • 14.11 Bristol-Myers Squibb Company
    • Company Overview
    • Psychotic Disorder Treatment Business Overview
    • New Product Development
    • Merger, Acquisition, and Collaboration
    • Certification and Licensing

15. Appendix

  • 15.1 List of Figures
  • 15.2 List of Tables
  • 15.3 Research Methodology
  • 15.4 Disclaimer
  • 15.5 Copyright
  • 15.6 Abbreviations and Technical Units
  • 15.7 About Us
  • 15.8 Contact Us

List of Figures

  • Figure 1.1: Trends and Forecast for the Global Psychotic Disorder Treatment Market
  • Figure 2.1: Usage of Psychotic Disorder Treatment Market
  • Figure 2.2: Classification of the Global Psychotic Disorder Treatment Market
  • Figure 2.3: Supply Chain of the Global Psychotic Disorder Treatment Market
  • Figure 3.1: Driver and Challenges of the Psychotic Disorder Treatment Market
  • Figure 3.2: PESTLE Analysis
  • Figure 3.3: Patent Analysis
  • Figure 3.4: Regulatory Environment
  • Figure 4.1: Global Psychotic Disorder Treatment Market by Drug Type in 2019, 2024, and 2031
  • Figure 4.2: Trends of the Global Psychotic Disorder Treatment Market ($B) by Drug Type
  • Figure 4.3: Forecast for the Global Psychotic Disorder Treatment Market ($B) by Drug Type
  • Figure 4.4: Trends and Forecast for Atypical Antipsychotics in the Global Psychotic Disorder Treatment Market (2019-2031)
  • Figure 4.5: Trends and Forecast for Phenothiazine Antipsychotics in the Global Psychotic Disorder Treatment Market (2019-2031)
  • Figure 4.6: Trends and Forecast for Thioxanthenes in the Global Psychotic Disorder Treatment Market (2019-2031)
  • Figure 4.7: Trends and Forecast for Miscellaneous Antipsychotics Agents in the Global Psychotic Disorder Treatment Market (2019-2031)
  • Figure 5.1: Global Psychotic Disorder Treatment Market by Indication in 2019, 2024, and 2031
  • Figure 5.2: Trends of the Global Psychotic Disorder Treatment Market ($B) by Indication
  • Figure 5.3: Forecast for the Global Psychotic Disorder Treatment Market ($B) by Indication
  • Figure 5.4: Trends and Forecast for Schizophrenia in the Global Psychotic Disorder Treatment Market (2019-2031)
  • Figure 5.5: Trends and Forecast for Bipolar Disorder in the Global Psychotic Disorder Treatment Market (2019-2031)
  • Figure 5.6: Trends and Forecast for Delusional Disorder in the Global Psychotic Disorder Treatment Market (2019-2031)
  • Figure 5.7: Trends and Forecast for Drug Induced Psychosis in the Global Psychotic Disorder Treatment Market (2019-2031)
  • Figure 5.8: Trends and Forecast for Organic Psychosis in the Global Psychotic Disorder Treatment Market (2019-2031)
  • Figure 6.1: Global Psychotic Disorder Treatment Market by Distribution Channel in 2019, 2024, and 2031
  • Figure 6.2: Trends of the Global Psychotic Disorder Treatment Market ($B) by Distribution Channel
  • Figure 6.3: Forecast for the Global Psychotic Disorder Treatment Market ($B) by Distribution Channel
  • Figure 6.4: Trends and Forecast for Hospital Pharmacies in the Global Psychotic Disorder Treatment Market (2019-2031)
  • Figure 6.5: Trends and Forecast for Retail Pharmacies in the Global Psychotic Disorder Treatment Market (2019-2031)
  • Figure 6.6: Trends and Forecast for Drug Store in the Global Psychotic Disorder Treatment Market (2019-2031)
  • Figure 6.7: Trends and Forecast for e-Commerce in the Global Psychotic Disorder Treatment Market (2019-2031)
  • Figure 6.8: Trends and Forecast for Others in the Global Psychotic Disorder Treatment Market (2019-2031)
  • Figure 7.1: Trends of the Global Psychotic Disorder Treatment Market ($B) by Region (2019-2024)
  • Figure 7.2: Forecast for the Global Psychotic Disorder Treatment Market ($B) by Region (2025-2031)
  • Figure 8.1: North American Psychotic Disorder Treatment Market by Drug Type in 2019, 2024, and 2031
  • Figure 8.2: Trends of the North American Psychotic Disorder Treatment Market ($B) by Drug Type (2019-2024)
  • Figure 8.3: Forecast for the North American Psychotic Disorder Treatment Market ($B) by Drug Type (2025-2031)
  • Figure 8.4: North American Psychotic Disorder Treatment Market by Distribution Channel in 2019, 2024, and 2031
  • Figure 8.5: Trends of the North American Psychotic Disorder Treatment Market ($B) by Distribution Channel (2019-2024)
  • Figure 8.6: Forecast for the North American Psychotic Disorder Treatment Market ($B) by Distribution Channel (2025-2031)
  • Figure 8.7: Trends and Forecast for the United States Psychotic Disorder Treatment Market ($B) (2019-2031)
  • Figure 8.8: Trends and Forecast for the Mexican Psychotic Disorder Treatment Market ($B) (2019-2031)
  • Figure 8.9: Trends and Forecast for the Canadian Psychotic Disorder Treatment Market ($B) (2019-2031)
  • Figure 9.1: European Psychotic Disorder Treatment Market by Drug Type in 2019, 2024, and 2031
  • Figure 9.2: Trends of the European Psychotic Disorder Treatment Market ($B) by Drug Type (2019-2024)
  • Figure 9.3: Forecast for the European Psychotic Disorder Treatment Market ($B) by Drug Type (2025-2031)
  • Figure 9.4: European Psychotic Disorder Treatment Market by Distribution Channel in 2019, 2024, and 2031
  • Figure 9.5: Trends of the European Psychotic Disorder Treatment Market ($B) by Distribution Channel (2019-2024)
  • Figure 9.6: Forecast for the European Psychotic Disorder Treatment Market ($B) by Distribution Channel (2025-2031)
  • Figure 9.7: Trends and Forecast for the German Psychotic Disorder Treatment Market ($B) (2019-2031)
  • Figure 9.8: Trends and Forecast for the French Psychotic Disorder Treatment Market ($B) (2019-2031)
  • Figure 9.9: Trends and Forecast for the Spanish Psychotic Disorder Treatment Market ($B) (2019-2031)
  • Figure 9.10: Trends and Forecast for the Italian Psychotic Disorder Treatment Market ($B) (2019-2031)
  • Figure 9.11: Trends and Forecast for the United Kingdom Psychotic Disorder Treatment Market ($B) (2019-2031)
  • Figure 10.1: APAC Psychotic Disorder Treatment Market by Drug Type in 2019, 2024, and 2031
  • Figure 10.2: Trends of the APAC Psychotic Disorder Treatment Market ($B) by Drug Type (2019-2024)
  • Figure 10.3: Forecast for the APAC Psychotic Disorder Treatment Market ($B) by Drug Type (2025-2031)
  • Figure 10.4: APAC Psychotic Disorder Treatment Market by Distribution Channel in 2019, 2024, and 2031
  • Figure 10.5: Trends of the APAC Psychotic Disorder Treatment Market ($B) by Distribution Channel (2019-2024)
  • Figure 10.6: Forecast for the APAC Psychotic Disorder Treatment Market ($B) by Distribution Channel (2025-2031)
  • Figure 10.7: Trends and Forecast for the Japanese Psychotic Disorder Treatment Market ($B) (2019-2031)
  • Figure 10.8: Trends and Forecast for the Indian Psychotic Disorder Treatment Market ($B) (2019-2031)
  • Figure 10.9: Trends and Forecast for the Chinese Psychotic Disorder Treatment Market ($B) (2019-2031)
  • Figure 10.10: Trends and Forecast for the South Korean Psychotic Disorder Treatment Market ($B) (2019-2031)
  • Figure 10.11: Trends and Forecast for the Indonesian Psychotic Disorder Treatment Market ($B) (2019-2031)
  • Figure 11.1: ROW Psychotic Disorder Treatment Market by Drug Type in 2019, 2024, and 2031
  • Figure 11.2: Trends of the ROW Psychotic Disorder Treatment Market ($B) by Drug Type (2019-2024)
  • Figure 11.3: Forecast for the ROW Psychotic Disorder Treatment Market ($B) by Drug Type (2025-2031)
  • Figure 11.4: ROW Psychotic Disorder Treatment Market by Distribution Channel in 2019, 2024, and 2031
  • Figure 11.5: Trends of the ROW Psychotic Disorder Treatment Market ($B) by Distribution Channel (2019-2024)
  • Figure 11.6: Forecast for the ROW Psychotic Disorder Treatment Market ($B) by Distribution Channel (2025-2031)
  • Figure 11.7: Trends and Forecast for the Middle Eastern Psychotic Disorder Treatment Market ($B) (2019-2031)
  • Figure 11.8: Trends and Forecast for the South American Psychotic Disorder Treatment Market ($B) (2019-2031)
  • Figure 11.9: Trends and Forecast for the African Psychotic Disorder Treatment Market ($B) (2019-2031)
  • Figure 12.1: Porter's Five Forces Analysis of the Global Psychotic Disorder Treatment Market
  • Figure 12.2: Market Share (%) of Top Players in the Global Psychotic Disorder Treatment Market (2024)
  • Figure 13.1: Growth Opportunities for the Global Psychotic Disorder Treatment Market by Drug Type
  • Figure 13.2: Growth Opportunities for the Global Psychotic Disorder Treatment Market by Indication
  • Figure 13.3: Growth Opportunities for the Global Psychotic Disorder Treatment Market by Distribution Channel
  • Figure 13.4: Growth Opportunities for the Global Psychotic Disorder Treatment Market by Region
  • Figure 13.5: Emerging Trends in the Global Psychotic Disorder Treatment Market

List of Tables

  • Table 1.1: Growth Rate (%, 2023-2024) and CAGR (%, 2025-2031) of the Psychotic Disorder Treatment Market by Drug Type, Indication, and Distribution Channel
  • Table 1.2: Attractiveness Analysis for the Psychotic Disorder Treatment Market by Region
  • Table 1.3: Global Psychotic Disorder Treatment Market Parameters and Attributes
  • Table 3.1: Trends of the Global Psychotic Disorder Treatment Market (2019-2024)
  • Table 3.2: Forecast for the Global Psychotic Disorder Treatment Market (2025-2031)
  • Table 4.1: Attractiveness Analysis for the Global Psychotic Disorder Treatment Market by Drug Type
  • Table 4.2: Market Size and CAGR of Various Drug Type in the Global Psychotic Disorder Treatment Market (2019-2024)
  • Table 4.3: Market Size and CAGR of Various Drug Type in the Global Psychotic Disorder Treatment Market (2025-2031)
  • Table 4.4: Trends of Atypical Antipsychotics in the Global Psychotic Disorder Treatment Market (2019-2024)
  • Table 4.5: Forecast for Atypical Antipsychotics in the Global Psychotic Disorder Treatment Market (2025-2031)
  • Table 4.6: Trends of Phenothiazine Antipsychotics in the Global Psychotic Disorder Treatment Market (2019-2024)
  • Table 4.7: Forecast for Phenothiazine Antipsychotics in the Global Psychotic Disorder Treatment Market (2025-2031)
  • Table 4.8: Trends of Thioxanthenes in the Global Psychotic Disorder Treatment Market (2019-2024)
  • Table 4.9: Forecast for Thioxanthenes in the Global Psychotic Disorder Treatment Market (2025-2031)
  • Table 4.10: Trends of Miscellaneous Antipsychotics Agents in the Global Psychotic Disorder Treatment Market (2019-2024)
  • Table 4.11: Forecast for Miscellaneous Antipsychotics Agents in the Global Psychotic Disorder Treatment Market (2025-2031)
  • Table 5.1: Attractiveness Analysis for the Global Psychotic Disorder Treatment Market by Indication
  • Table 5.2: Market Size and CAGR of Various Indication in the Global Psychotic Disorder Treatment Market (2019-2024)
  • Table 5.3: Market Size and CAGR of Various Indication in the Global Psychotic Disorder Treatment Market (2025-2031)
  • Table 5.4: Trends of Schizophrenia in the Global Psychotic Disorder Treatment Market (2019-2024)
  • Table 5.5: Forecast for Schizophrenia in the Global Psychotic Disorder Treatment Market (2025-2031)
  • Table 5.6: Trends of Bipolar Disorder in the Global Psychotic Disorder Treatment Market (2019-2024)
  • Table 5.7: Forecast for Bipolar Disorder in the Global Psychotic Disorder Treatment Market (2025-2031)
  • Table 5.8: Trends of Delusional Disorder in the Global Psychotic Disorder Treatment Market (2019-2024)
  • Table 5.9: Forecast for Delusional Disorder in the Global Psychotic Disorder Treatment Market (2025-2031)
  • Table 5.10: Trends of Drug Induced Psychosis in the Global Psychotic Disorder Treatment Market (2019-2024)
  • Table 5.11: Forecast for Drug Induced Psychosis in the Global Psychotic Disorder Treatment Market (2025-2031)
  • Table 5.12: Trends of Organic Psychosis in the Global Psychotic Disorder Treatment Market (2019-2024)
  • Table 5.13: Forecast for Organic Psychosis in the Global Psychotic Disorder Treatment Market (2025-2031)
  • Table 6.1: Attractiveness Analysis for the Global Psychotic Disorder Treatment Market by Distribution Channel
  • Table 6.2: Market Size and CAGR of Various Distribution Channel in the Global Psychotic Disorder Treatment Market (2019-2024)
  • Table 6.3: Market Size and CAGR of Various Distribution Channel in the Global Psychotic Disorder Treatment Market (2025-2031)
  • Table 6.4: Trends of Hospital Pharmacies in the Global Psychotic Disorder Treatment Market (2019-2024)
  • Table 6.5: Forecast for Hospital Pharmacies in the Global Psychotic Disorder Treatment Market (2025-2031)
  • Table 6.6: Trends of Retail Pharmacies in the Global Psychotic Disorder Treatment Market (2019-2024)
  • Table 6.7: Forecast for Retail Pharmacies in the Global Psychotic Disorder Treatment Market (2025-2031)
  • Table 6.8: Trends of Drug Store in the Global Psychotic Disorder Treatment Market (2019-2024)
  • Table 6.9: Forecast for Drug Store in the Global Psychotic Disorder Treatment Market (2025-2031)
  • Table 6.10: Trends of e-Commerce in the Global Psychotic Disorder Treatment Market (2019-2024)
  • Table 6.11: Forecast for e-Commerce in the Global Psychotic Disorder Treatment Market (2025-2031)
  • Table 6.12: Trends of Others in the Global Psychotic Disorder Treatment Market (2019-2024)
  • Table 6.13: Forecast for Others in the Global Psychotic Disorder Treatment Market (2025-2031)
  • Table 7.1: Market Size and CAGR of Various Regions in the Global Psychotic Disorder Treatment Market (2019-2024)
  • Table 7.2: Market Size and CAGR of Various Regions in the Global Psychotic Disorder Treatment Market (2025-2031)
  • Table 8.1: Trends of the North American Psychotic Disorder Treatment Market (2019-2024)
  • Table 8.2: Forecast for the North American Psychotic Disorder Treatment Market (2025-2031)
  • Table 8.3: Market Size and CAGR of Various Drug Type in the North American Psychotic Disorder Treatment Market (2019-2024)
  • Table 8.4: Market Size and CAGR of Various Drug Type in the North American Psychotic Disorder Treatment Market (2025-2031)
  • Table 8.5: Market Size and CAGR of Various Distribution Channel in the North American Psychotic Disorder Treatment Market (2019-2024)
  • Table 8.6: Market Size and CAGR of Various Distribution Channel in the North American Psychotic Disorder Treatment Market (2025-2031)
  • Table 8.7: Trends and Forecast for the United States Psychotic Disorder Treatment Market (2019-2031)
  • Table 8.8: Trends and Forecast for the Mexican Psychotic Disorder Treatment Market (2019-2031)
  • Table 8.9: Trends and Forecast for the Canadian Psychotic Disorder Treatment Market (2019-2031)
  • Table 9.1: Trends of the European Psychotic Disorder Treatment Market (2019-2024)
  • Table 9.2: Forecast for the European Psychotic Disorder Treatment Market (2025-2031)
  • Table 9.3: Market Size and CAGR of Various Drug Type in the European Psychotic Disorder Treatment Market (2019-2024)
  • Table 9.4: Market Size and CAGR of Various Drug Type in the European Psychotic Disorder Treatment Market (2025-2031)
  • Table 9.5: Market Size and CAGR of Various Distribution Channel in the European Psychotic Disorder Treatment Market (2019-2024)
  • Table 9.6: Market Size and CAGR of Various Distribution Channel in the European Psychotic Disorder Treatment Market (2025-2031)
  • Table 9.7: Trends and Forecast for the German Psychotic Disorder Treatment Market (2019-2031)
  • Table 9.8: Trends and Forecast for the French Psychotic Disorder Treatment Market (2019-2031)
  • Table 9.9: Trends and Forecast for the Spanish Psychotic Disorder Treatment Market (2019-2031)
  • Table 9.10: Trends and Forecast for the Italian Psychotic Disorder Treatment Market (2019-2031)
  • Table 9.11: Trends and Forecast for the United Kingdom Psychotic Disorder Treatment Market (2019-2031)
  • Table 10.1: Trends of the APAC Psychotic Disorder Treatment Market (2019-2024)
  • Table 10.2: Forecast for the APAC Psychotic Disorder Treatment Market (2025-2031)
  • Table 10.3: Market Size and CAGR of Various Drug Type in the APAC Psychotic Disorder Treatment Market (2019-2024)
  • Table 10.4: Market Size and CAGR of Various Drug Type in the APAC Psychotic Disorder Treatment Market (2025-2031)
  • Table 10.5: Market Size and CAGR of Various Distribution Channel in the APAC Psychotic Disorder Treatment Market (2019-2024)
  • Table 10.6: Market Size and CAGR of Various Distribution Channel in the APAC Psychotic Disorder Treatment Market (2025-2031)
  • Table 10.7: Trends and Forecast for the Japanese Psychotic Disorder Treatment Market (2019-2031)
  • Table 10.8: Trends and Forecast for the Indian Psychotic Disorder Treatment Market (2019-2031)
  • Table 10.9: Trends and Forecast for the Chinese Psychotic Disorder Treatment Market (2019-2031)
  • Table 10.10: Trends and Forecast for the South Korean Psychotic Disorder Treatment Market (2019-2031)
  • Table 10.11: Trends and Forecast for the Indonesian Psychotic Disorder Treatment Market (2019-2031)
  • Table 11.1: Trends of the ROW Psychotic Disorder Treatment Market (2019-2024)
  • Table 11.2: Forecast for the ROW Psychotic Disorder Treatment Market (2025-2031)
  • Table 11.3: Market Size and CAGR of Various Drug Type in the ROW Psychotic Disorder Treatment Market (2019-2024)
  • Table 11.4: Market Size and CAGR of Various Drug Type in the ROW Psychotic Disorder Treatment Market (2025-2031)
  • Table 11.5: Market Size and CAGR of Various Distribution Channel in the ROW Psychotic Disorder Treatment Market (2019-2024)
  • Table 11.6: Market Size and CAGR of Various Distribution Channel in the ROW Psychotic Disorder Treatment Market (2025-2031)
  • Table 11.7: Trends and Forecast for the Middle Eastern Psychotic Disorder Treatment Market (2019-2031)
  • Table 11.8: Trends and Forecast for the South American Psychotic Disorder Treatment Market (2019-2031)
  • Table 11.9: Trends and Forecast for the African Psychotic Disorder Treatment Market (2019-2031)
  • Table 12.1: Product Mapping of Psychotic Disorder Treatment Suppliers Based on Segments
  • Table 12.2: Operational Integration of Psychotic Disorder Treatment Manufacturers
  • Table 12.3: Rankings of Suppliers Based on Psychotic Disorder Treatment Revenue
  • Table 13.1: New Product Launches by Major Psychotic Disorder Treatment Producers (2019-2024)
  • Table 13.2: Certification Acquired by Major Competitor in the Global Psychotic Disorder Treatment Market